...
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Women and the management of acute coronary syndrome
【24h】

Women and the management of acute coronary syndrome

机译:妇女与急性冠脉综合征的管理

获取原文
获取原文并翻译 | 示例
           

摘要

Coronary heart disease (CHD) is the leading cause of morbidity and mortality in both men and women in the developed countries. despite this fact, females are still under-represented in the majority of clinical trials. At the present time, only limited evidence is available with respect to the female-specific aspects of pathogenesis, management, and outcomes in acute coronary syndrome (ACS). Women less frequently undergo coronary intervention, and a lower proportion of women receive evidence-based pharmacotherapy, compared with men. It has been shown that women benefit from an invasive approach and coronary intervention in ACS as much as men, despite their advanced age and higher rate of bleeding complications. Also, administration of beta-blockers, ACE-inhibitors, and intensive statin therapy is associated with a comparable reduction of cardiovascular event rates in women and men. On the other hand, women may profit less than men from fibri-nolytic or glycoprotein IIb/IIIa inhibitor therapy. Both sexes benefit equally from aspirin therapy, whereas contradictory data are available on the efficacy of clopidogrel in women. There is an urgent need for intensive research in the development of female-specific therapeutic strategy in ACS, even though the detailed mechanisms of sex differences are still unknown.
机译:冠心病(CHD)是发达国家男女的发病率和死亡率的主要原因。尽管有这个事实,但大多数临床试验中女性的代表性仍然不足。目前,关于急性冠状动脉综合征(ACS)的发病机制,治疗和预后方面的女性特异性方面,仅有有限的证据。与男性相比,女性接受冠脉介入治疗的频率降低,女性接受循证药物治疗的比例更低。研究表明,尽管女性高龄且出血并发症发生率较高,但与男性一样,女性从侵入性治疗和冠状动脉介入治疗中受益的程度与男性相同。同样,在男性和女性中,使用β受体阻滞剂,ACEI抑制剂和强化他汀类药物治疗与降低心血管事件发生率相关。另一方面,女性从纤溶酶或糖蛋白IIb / IIIa抑制剂治疗中获得的利润可能比男性少。男女平等地从阿司匹林治疗中受益,而关于氯吡格雷在女性中的疗效却存在矛盾的数据。尽管性别差异的详细机制仍然未知,但迫切需要对ACS的女性特异性治疗策略进行深入研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号